$SWIM

River AI, founded by Igor Babuschkin, raised $1.1B in funding led by General Catalyst and AMP PBC, with strategic investments from AMD and NVIDIA. The funds will support its AI development and tools for developers. Latham & Watkins advised AMD in the transaction.

StepStone Group Inc. (STEP) closed a $1.7 billion fundraise for its StepStone Secondaries Infrastructure Fund. Latham & Watkins LLP advised on the fund formation, with contributions from multiple partners and associates across various legal and regulatory matters.

Ursa Major Technologies (private) will merge with SPAC Bleichroeder Acquisition Corp. (Nasdaq: BCCQU), forming Inflection Point Mach X Bleichroeder (Nasdaq: IPXX). The deal is valued at US$2.3 billion, with US$350 million in PIPE commitments. Latham & Watkins advised Ursa Major on the transaction.

Roots Corporation (TSX: ROOT) will be acquired by Marquee Brands, backed by Neuberger Berman, with JM&A Design and Development Inc. as the operating partner. The deal aims to expand Roots' global presence while maintaining its Canadian operations. Latham & Watkins advised on the financing.

Swvl Holdings (Nasdaq: SWVL) has secured a strategic investment from Coefficient LP, a US firm backed by the Sawiris family. Upon closing, Coefficient will become Swvl's largest institutional shareholder. Latham & Watkins advised Coefficient in the transaction.

Latham Group (SWIM) refinanced its capital structure with new credit facilities totaling $375 million. The facilities include a $75 million revolving credit line and a $300 million term loan, both secured by company assets. Proceeds were used to repay existing debt. The facilities mature in 2031 and 2033, respectively, and include leverage-based interest margins and covenants.

Werewolf Therapeutics (HOWL) and Ambros Therapeutics agreed to merge in an all-stock deal. The combined company will focus on Ambros' neridronate program for CRPS-1 and trade as AMBX. They secured $150M in private placement from healthcare investors. Latham & Watkins advised on the transaction.

Gossamer Bio (GOSS) plans a private placement of up to $250M, including $150M committed capital. The deal involves new and existing investors and is contingent on FDA actions for seralutinib. Latham & Watkins advised the company. The financing follows Gossamer's reacquisition of seralutinib rights and precedes its planned NDA submission in September 2026.

Andersen Group Inc. announced a secondary offering of 4.28 million shares of Class A common stock at $44 per share, with gross proceeds of $188.5 million for selling stockholders. The offering is expected to close on August 21, 2026, with underwriters having a 30-day option to purchase additional shares. Andersen is not selling shares and will not receive proceeds. Latham & Watkins LLP represents the underwriters.

Latham Group (SWIM) secured $375 million in new credit facilities, including a $75 million revolving credit line and a $300 million term loan, led by Jefferies Finance. The facilities will refinance and extend the company's maturities, replacing a 2022 Barclays-led agreement. The revolver matures in 2031, and the term loan in 2033.